November 24th 2024
The FDA received a biologics license application for accelerated approval of RP1 plus nivolumab for advanced, pretreated melanoma.
September 21st 2024
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hematology Meeting: Preceding the 66th ASH Annual Meeting and Exposition
December 6, 2024
Register Now!
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Sancy Leachman on Patients at High Risk for Melanoma
January 16th 2016Sancy Leachman, MD, PhD, professor and chair, Department of Dermatology, director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses patients who are at high risk for developing melanoma.
Sancy Leachman on Monitoring for Melanoma Recurrences
December 28th 2015Sancy Leachman, MD, PhD, professor and chair, Department of Dermatology, director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses how a mobile app can help oncology professionals monitor patients for melanoma.
John Kirkwood on Training Physicians on Skin Examinations
December 3rd 2015John Kirkwood, MD, Usher professor, Medicine, Dermatology and Translational Science, co-director, Melanoma and Skin Cancer Program, University of Pittsburgh, discusses training physicians on skin examinations for detecting melanoma.Â
Sancy Leachman on the Mole Mapping App
December 2nd 2015Sancy Leachman, MD, PhD, professor and chair, Department of Dermatology, director, Melanoma Research Program, Knight Cancer Institute, Oregon Health & Science University, discusses the mobile app Mole Mapper, which allows patients to measure and monitor their moles for melanoma.
The FDA Expands Approval of Opdivo as Frontline Therapy for Melanoma
November 24th 2015The FDA has approved nivolumab (Opdivo) as a frontline treatment for patients with BRAF wild-type advanced melanoma, based on a substantial improvement in overall survival (OS) compared with dacarbazine in a phase III study.
Tafinlar/Mekinist Combination Fully Approved by FDA for BRAF-Mutant Melanoma
November 23rd 2015The combination of Tafinlar (dabrafenib) and Mekinist (trametinib) has been fully approved by the FDA to treat patients with unresectable or metastatic BRAF-mutated melanoma. The approval is based on an extension in overall survival (OS) from two phase III studies.
Melanoma Treatments Are Advancing, But Next Steps Remain Unclear
November 20th 2015In this interview to gain further insight into the flurry of FDA activity, Tim Turnham, executive director of the Melanoma Research Foundation, sheds light on the recent drug approvals and what's next for treating melanoma.
First Oncolytic Immunotherapy Approved for Advanced Melanoma
October 28th 2015The FDA has approved the first-in-class oncolytic viral therapy Imlygic (T-VEC; talimogene laherparepvec) for the local treatment of unresectable lesions of the skin and lymph nodes in patients with melanoma that recurred after initial surgery.
More Evidence That Patients With Cancer Need Careful Monitoring for Distress
October 7th 2014A new study has found that nearly one third of cancer patients suffer from anxiety or other mental health challenges, with breast cancer patients, head and neck cancer patients and melanoma patients suffering the most.